LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF

Exclusion Criteria

• •1. A diagnosis of PH WHO Groups 1, 3, 4, or 5.
• •2. Echocardiographic evidence for hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy
• •3. Structural heart repair or replacement of the aortic valve or mitral valve (surgical or percutaneous). OR, planned valve intervention. OR, the presence of significant valve disease
• •4. A diagnosis of pre-existing lung disease
• •5. History of severe allergic or anaphylactic reaction or hypersensitivity to the excipients in the investigational product.
• •6. Major surgery within 60 days.
• •7. Prior heart, lung, or heart-lung transplants or life expectancy of \<12 months
• •8. History of clinically significant other diseases that may limit or complicate participation in the study.